Clinical trials: Soft-tissue Sarcomas
Prostate Cancer, Other Solid Tumors
A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC008 in patients with…
- Conditions
- Prostate Cancer, Other Solid Tumors, Ewing Sarcoma
- Trial name
- NCT06926283
- Testing
- DXC008
- Where
- 4 sites in China
- Volunteers
- 110 people
- Sponsor
- Hangzhou DAC Biotechnology Co., Ltd.
Lung Cancer, Esophageal Cancer
Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
Background: Certain types of lung, esophageal, or thymic cancers and mesotheliomas have specific antigens (protein molecules) on their surfaces.
- Conditions
- Lung Cancer, Esophageal Cancer, Malignant Pleural Mesothelioma, Sarcoma
- Trial name
- NCT01143545
- Testing
- Allogeneic Tumor Cell Vaccine (K562), Celecoxib, cyclophosphamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Pleuropulmonary Blastoma, Cystic Nephroma
Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome
Pleuropulmonary Blastoma (PPB) is a rare lung tumor which develops in childhood. The underlying genetic factors which contribute to the development and progression of PPB are not defined.
- Conditions
- Pleuropulmonary Blastoma, Cystic Nephroma, Sertoli-Leydig Cell Tumor of Ovary, Medulloepithelioma
- Trial name
- PPB (NCT00565903)
- Where
- United States
- Volunteers
- 1,247 people, healthy volunteers welcome
- Sponsor
- Ashley Hill
Kaposi Sarcoma
Propranolol for the Treatment of Kaposi Sarcoma in Adults
Kaposi sarcoma (KS) lesions are initiated by endothelial cells infected with KS herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8).
- Trial name
- NCT06445166
- Testing
- Propranolol Hydrochloride
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Washington University School of Medicine
Soft Tissue Sarcoma
Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma
This study will assess the safety and efficacy of GPX-150 administered intravenously every 3 weeks in the treatment of patients with soft tissue sarcoma.
- Trial name
- NCT02267083
- Testing
- GPX-150 for Injection
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Gem Pharmaceuticals
Colorectal Carcinoma, Soft Tissue Sarcoma
Molecular Profiling to Improve Outcome of Patients in Cancer. A Pilot Study
Next Generation Sequencing in cancer: a feasibility study in France to assess sample circuit and to perform analyzes within a limited time.
- Trial name
- MULTIPLI-0 (NCT03546127)
- Testing
- Next Generation Sequencing (NGS): exome, RNA seq
- Where
- 3 sites in France
- Volunteers
- 24 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1
SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
To determine the clinical benefit rate of selumetinib in combination with sirolimus in patients with unresectable or metastatic neurofibromatosis type 1 (NF1) associated or sporadic MPNST.
- Trial name
- NCT03433183
- Testing
- Selumetinib, Sirolimus
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Solid Tumor, Adult, Cancer
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
AdAPT-001 is an oncolytic virus that is injected directly into the tumor or via intraarterial administration. The purpose of this study is to find out if AdAPT-001 is safe and tolerable.
- Conditions
- Solid Tumor, Adult, Cancer, Neoplasms, Sarcoma
- Trial name
- BETA-PRIME (NCT04673942)
- Testing
- AdAPT-001, Checkpoint Inhibitor, Immune
- Where
- 6 sites in United States
- Volunteers
- 140 people
- Sponsor
- EpicentRx, Inc.
Sarcoma
A Study of Pemetrexed Plus Cisplatin in Patients With Refractory Soft Tissue Sarcoma
The yearly incidence of soft-tissue sarcomas(STS) in the USA is roughly 11,280 cases, and metastatic STS have a median overall survival of about 12 months.
- Trial name
- NCT03809637
- Testing
- Pemetrexed, cisplatin
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Yonsei University
Osteosarcoma, Ewing Sarcoma of Bone
Regorafenib in Patients With Refractory Primary Bone Tumors
The aim of the project is to improve treatment outcomes in patients with primary malignant bone tumors, refractory to standard therapy, by increasing the availability of advanced therapy, as well as to develop treatment options…
- Trial name
- Regbone (NCT05395741)
- Testing
- Regorafenib
- Where
- 2 sites in Poland
- Volunteers
- 30 people
- Sponsor
- Institute of Mother and Child, Warsaw, Poland
Tumor
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves…
- Trial name
- NCT00413322
- Testing
- belinostat, 5-Fluorouracil (5-FU)
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Valerio Therapeutics
Solid Tumor
Pazopanib and ARQ 197 for Advanced Solid Tumors
Background: Pazopanib is an anticancer drug that blocks the growth of new blood vessels in tumors. It has been approved to treat renal cell cancer and soft tissue sarcomas in patients who have received prior chemotherapy.
- Trial name
- NCT01468922
- Testing
- Pazopanib, ARQ 197
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Angiosarcoma
Propranolol in Angiosarcoma
This is a window opportunity study of propranolol in patients with angiosarcoma. The aim of this study is to prospectively evaluate the activity of propranolol in the clinical setting as monotherapy, where the neoadjuvant setting…
- Trial name
- NCT04518124
- Testing
- Propranolol
- Where
- Netherlands
- Volunteers
- 14 people
- Sponsor
- The Netherlands Cancer Institute
Conventional Chondrosarcoma, Myxoid Liposarcoma
Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma
Chondrosarcoma and liposarcoma consists of different subtypes with a wide range of patient survival. Current treatment options consist of wide surgical resection, however for patients with a local recurrence or metastatic disease…
- Conditions
- Conventional Chondrosarcoma, Myxoid Liposarcoma, Mesenchymal Chondrosarcoma, Dedifferentiated Chondrosarcoma
- Trial name
- NCT02821507
- Testing
- sirolimus and cyclophosphamide
- Where
- 7 sites in Netherlands, Spain
- Volunteers
- 70 people
- Sponsor
- Leiden University Medical Center
Soft Tissue Sarcoma
Exercise and Soft Tissue Sarcoma
The purpose of this study is to evaluate the effect of a neoadjuvant (i.e. pre-treatment) exercise regimen on extremity function and postoperative wound healing.
- Trial name
- NCT04921917
- Testing
- neoadjuvant exercise therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Duke University
Adenocarcinoma, Basal Cell Carcinoma
Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
This is a pilot clinical trial determining the effect of a Methionine-reduced diet on serum levels in subjects with solid tumors. These are subjects who will receive systemic standard of care cancer therapy.
- Conditions
- Adenocarcinoma, Basal Cell Carcinoma, Squamous Cell Carcinoma, Transitional Cell Carcinoma
- Trial name
- NCT07628634
- Testing
- Methionine-Reduced Diet
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of California, Irvine
Soft Tissue Sarcoma
A Phase 2 Study Using Aliya PEF Plus Pembro for Sarcoma
The is a phase 2 that will evaluate the efficacy and safety of the Aliya PEF ablation system combined with pembrolizumab, an immune checkpoint inhibitor.in advanced soft tissue sarcoma. Twenty subjects will be treated.
- Trial name
- SOC-2320 (NCT06494787)
- Testing
- Aliya Pulse Electric Field sysem and pembrolizumab
- Sponsor
- Sarcoma Oncology Research Center, LLC
Solid Tumor
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
This is a multi-center, open-label Phase 0 Master Protocol designed to study the localized pharmacodynamics (PD) of anti-cancer therapies within the tumor microenvironment (TME) when administered intratumorally in microdose…
- Trial name
- NCT04541108
- Testing
- Rilvegostomig, Volrustomig, Sabestomig
- Where
- 9 sites in United States
- Volunteers
- 15 people
- Sponsor
- Presage Biosciences
Sarcoma
Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma
RATIONALE: Drugs used in chemotherapy, such as liposomal daunorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00427414
- Testing
- liposomal daunorubicin citrate
- Where
- 3 sites in United States, Brazil
- Volunteers
- 14 people
- Sponsor
- AIDS Malignancy Consortium
Sarcoma
MRI Sarcoma Non Invasive Thermometry
RATIONALE: Hyperthermia therapy kills tumor cells by heating them to several degrees above body temperature. Using MRI to measure heat may help to determine the effectiveness of hyperthermia therapy.
- Trial name
- NCT00093509
- Testing
- doxorubicin hydrochloride, ifosfamide and mesna, hyperthermia treatment with an MRI Compatible Radiofrequency Extremity Hyperthermia Applicator
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mark Dewhirst
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.